Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200

PURPOSE: Samalizumab is a novel recombinant humanized monoclonal antibody that targets CD200, an immunoregulatory cell surface member of the immunoglobulin superfamily that dampens excessive immune responses and maintains self-tolerance. This first-in-human study investigated the therapeutic use of...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahadevan, Daruka, Lanasa, Mark C., Farber, Charles, Pandey, Manjari, Whelden, Maria, Faas, Susan J., Ulery, Terrie, Kukreja, Anjli, Li, Lan, Bedrosian, Camille L., Zhang, Xiaoping, Heffner, Leonard T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708181/
https://www.ncbi.nlm.nih.gov/pubmed/31443741
http://dx.doi.org/10.1186/s40425-019-0710-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708181/
https://www.ncbi.nlm.nih.gov/pubmed/31443741
http://dx.doi.org/10.1186/s40425-019-0710-1

Ejemplares similares